| Gene symbol | GPRC5D | Synonyms | None | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p13.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | G protein-coupled receptor class C group 5 member D | ||||
| GTO ID | GTC3656 |
| Trial ID | NCT06121843 |
| Disease | Multiple Myeloma |
| Altered gene | GPRC5D |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BMS-986393|CC-95266 |
| Co-treatment | Alnuctamab |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component |
| Year | 2024 |
| Country | Canada|United States |
| Company sponsor | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
| Other ID(s) | CA088-1005 |
| Cohort1: CAR-T_Alnuctamab | |||||
|
|||||
| Cohort2: CAR-T_Mezigdomide | |||||
|
|||||
| Cohort3: CAR-T_Iberdomide | |||||
|
|||||